Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Q&AUpdated 8 min read

CJC-1295 side effects, alone and with ipamorelin

CJC-1295 side effects in small human trials included injection site reactions, headache, flushing, and a faster heart rate. The ipamorelin blend is untested. Neither peptide is FDA approved.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer: in the only published human trials, CJC-1295 most often caused injection site reactions, headache, flushing, and diarrhea, and FDA has flagged serious events including a faster heart rate and a whole body vasodilatory reaction. [3] [4] Those trials were small and short, CJC-1295 has never been approved anywhere, and it is not on the 503A bulks list, so a 503A pharmacy has no federal basis to compound it from bulk.

This post covers what the studies recorded, the side effects expected from raising growth hormone and IGF-1 for long periods, what is known when CJC-1295 is combined with ipamorelin, and where CJC-1295 stands legally. It does not give dosing advice.

What is CJC-1295?

CJC-1295 is a lab-made version of growth hormone releasing hormone, altered so that it binds to albumin in the blood and lasts about a week. In healthy adults, one injection raised growth hormone 2 to 10 fold for 6 or more days and IGF-1 1.5 to 3 fold for 9 to 11 days. [1] A second study found that growth hormone kept its natural pulses but that baseline levels between pulses rose about 7.5 fold. [2]

That long action is the selling point, and it is also the reason side effects matter: once it is injected, the exposure cannot be switched off for days.

What side effects did the human studies report?

The human safety data come from two randomized, placebo controlled trials in healthy adults, published in 2006, plus a small single dose study. [1] [2] The published abstract reported no serious adverse reactions. [1] FDA's 2024 review of the full papers, covering 63 healthy adults, lists what did happen: [3]

Adverse events reported in the CJC-1295 trials in healthy adults, as summarized by FDA
Side effectWhat was reported
Injection site reactions

About 70% in one study and all participants in the other; irritation, redness, hardness, pain, or itching, worse at higher doses

Headache

63% versus 14% on placebo in one study; 20% to 80% by dose group versus 50% on placebo in the other

Diarrhea or loose stools43% in one study, none on placebo
Flushing, warmth, and brief low blood pressure30% in one study, none on placebo
Nausea or abdominal pain20%, none on placebo
Rarer events

Dizziness with low blood pressure after a first injection (two people); involuntary leg muscle contractions with some loss of coordination (one person)

The authors reported no consistent changes in blood or urine tests, glucose, liver tests, or heart tracings. [3] In the single dose study in young men, FDA notes a dose dependent rise in heart rate and short lived redness and tenderness at the injection site. [3]

Were there serious side effects?

FDA's compounding risk list states that it has identified serious adverse events with CJC-1295, including increased heart rate and a systemic vasodilatory reaction, and that available clinical data are limited. [4]

FDA's briefing document also describes a phase 2 trial in people with HIV lipodystrophy that was terminated after a participant died of a heart attack. The attending physician's most likely explanation was undiagnosed coronary artery disease, and the trial's data were never published. [3] One case cannot show that the drug caused the death. The developer withdrew CJC-1295 from clinical trials after it, and FDA found no published study testing whether it works in patients; the only published human studies were in healthy adults. [3]

Animal studies raised further flags. FDA describes bleeding, inflammation, and tissue death at injection sites in rats and dogs given repeated injections, signs of genetic damage in lab tests, and a possible risk of pituitary overgrowth or tumors with long term use that has never been ruled out. [3]

What side effects come from raising growth hormone and IGF-1?

CJC-1295 works by pushing the body's own growth hormone and IGF-1 higher for days at a time. [1] No CJC-1295 study lasted long enough to measure the effects that sustained growth hormone exposure causes, so the best guide is what happens with growth hormone itself.

The FDA label for somatropin, prescription growth hormone, warns about: [6]

  • Fluid retention, including swelling, joint pain, and carpal tunnel syndrome, which it says may occur frequently in adults.
  • Impaired glucose tolerance and diabetes, which growth hormone may unmask.
  • Tumor growth, with advice to monitor people with existing tumors for progression or recurrence.
  • Raised pressure inside the skull, thyroid and adrenal changes, and pancreatitis.

A systematic review of growth hormone in healthy older adults found more swelling, joint pain, carpal tunnel syndrome, and breast tissue growth in men, and a trend toward new diabetes and impaired fasting glucose. [7] Whether CJC-1295 raises IGF-1 enough, for long enough, to reproduce those effects has not been studied, which is itself the problem.

What are the side effects of CJC-1295 with ipamorelin?

Nobody knows for the pair itself. No published study has given CJC-1295 and ipamorelin together, in people or in animals, so no side effects have been recorded for the combination. What can be said comes from each peptide on its own and from reviews of growth hormone peptides as a class. The CJC-1295 and ipamorelin blend page covers the pairing in full.

  • The CJC-1295 half. The trial effects above apply: injection site reactions, headache, diarrhea, and flushing with brief low blood pressure, plus the faster heart rate and vasodilatory reaction FDA cites as serious events. [3] [4]
  • The ipamorelin half. Ipamorelin acts on the ghrelin receptor rather than the GHRH receptor. Its only randomized human trial gave it intravenously for up to 7 days after bowel surgery: adverse events occurred in 87.5% of the ipamorelin group and 94.8% of the placebo group, and the authors called it well tolerated. [9] That trial used a different route and a different population than the injections sold today, and no CJC-1295. When FDA placed ipamorelin in Category 2 in 2023, it cited a risk of immune reactions from aggregation and peptide related impurities. [4]
  • Effects that could add up. In a 1990 study of healthy men, GHRH given together with a synthetic growth hormone releasing peptide released more growth hormone than either alone. [10] That study used different molecules and single intravenous doses, but it is the usual rationale for the pair, and it is why the growth hormone effects described above, such as fluid retention, joint pain, and higher blood sugar, could plausibly be larger with both. No study has measured this.
  • What reviews report. A 2026 review of growth hormone axis peptides used outside medical care, including CJC-1295 and ipamorelin, lists reported adverse effects: prolactin and cortisol rises, appetite changes, blood sugar problems, fluid retention, muscle and joint pain, and injection site reactions. It also notes uncertainty about what unregulated products contain and how they are combined. [11]

One more caution: the same review lists CJC-1295 with DAC and CJC-1295 without DAC as separate agents. [11] The published trials tested only the long acting version with DAC, so their side effect data may not describe a blend made with the version without it. [1]

Ipamorelin is not FDA approved and is not on the 503A bulks list either. Its 503A nomination was withdrawn, and ipamorelin acetate remains in 503B Category 2, so neither a 503A pharmacy nor a 503B outsourcing facility has a federal basis to compound it. [4] [5]

No. CJC-1295 has never been approved anywhere. FDA placed it on its Category 2 list of substances that may present significant safety risks in 2023, and its current bulks page lists it as a nominated but withdrawn substance, not on the 503A bulks list. [5] In its 2024 review, FDA proposed not adding any form of CJC-1295 to the bulks list, citing poor characterization, safety concerns, no evidence of effectiveness, and the existence of approved treatments for growth hormone deficiency. [3]

With no approved product and no bulks list entry, a 503A pharmacy has no federal basis to compound it from bulk. Clinic and "research use only" products therefore come with no FDA oversight of identity, purity, or sterility. The CJC-1295 regulatory tracker logs every status change, and the CJC-1295 cost page explains why there is no lawful price to list.

Is CJC-1295 allowed in sport?

No. The WADA Prohibited List places growth hormone releasing hormone and its analogues, including CJC-1295, in section S2, banned at all times in and out of competition. [8]

How does it compare with other growth hormone peptides?

Tesamorelin acts on the same receptor, is FDA approved for one indication, and has a full label of side effect data from phase 3 trials. Sermorelin is an older, short acting version with small human trials. See tesamorelin vs CJC-1295 and sermorelin vs CJC-1295. CJC-1295 is often sold blended with ipamorelin, a pairing never tested in humans; see CJC-1295 vs ipamorelin and the CJC-1295 and ipamorelin blend page. For the growth hormone question itself, read sermorelin vs HGH.

Talk to a clinician first

If you have used CJC-1295 and notice swelling, a racing heart, chest pain, or signs of high blood sugar, talk to a licensed clinician and bring the product label. If low growth hormone is the real concern, an endocrinologist can test for it; the growth hormone deficiency page lists the approved treatments.

What's actually offered, and what that means for you

FDA has found compounding pharmacies offering CJC-1295 anyway. [12] [13]

What that means for you

  • A pharmacy that compounds CJC-1295 is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [14] [15]
  • No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [16]
  • State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [17]
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [18] [19]

If you're going ahead anyway

Each step is on the CJC-1295 page: check the pharmacy's license, what a legitimate prescription and consult look like, why this is safer than a research-use-only product, and questions to ask. These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound CJC-1295, with or without a prescription. [5]

Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.

Frequently asked questions

What are the most common CJC-1295 side effects?

In the two small 2006 trials in healthy adults, injection site reactions were most common, affecting about 70% of people in one study. Headache, diarrhea, and flushing with warmth and a brief drop in blood pressure were also reported more often than on placebo. [3]

Were there serious side effects?

The published trials reported no serious adverse reactions. FDA separately cites serious adverse events including increased heart rate and a systemic vasodilatory reaction, and a phase 2 trial was stopped after a participant died of a heart attack that the attending physician attributed to undiagnosed coronary artery disease. [1] [3] [4]

What are the side effects of CJC-1295 with ipamorelin?

No study has tested the pair, so its side effects have never been recorded. CJC-1295 trials reported injection site reactions, headache, flushing, and diarrhea. Ipamorelin's one randomized trial, given intravenously after bowel surgery, found adverse events no more often than on placebo. A 2026 review of growth hormone peptides lists fluid retention, joint and muscle pain, appetite changes, and blood sugar problems. [3] [9] [11]

Is CJC-1295 FDA approved?

No. It was never approved anywhere, and FDA now lists it as a nominated but withdrawn bulk substance, so a 503A pharmacy has no federal basis to compound it from bulk. [4] [5]

Is CJC-1295 banned in sport?

Yes. The WADA Prohibited List covers growth hormone releasing hormone and its analogues, including CJC-1295, under section S2, prohibited at all times. [8]

Sources

Numbered citations in the article point to these primary sources. PubMed entries link to the indexed abstract. Evidence grades follow our methodology.

  1. [1]Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006PubMed 16352683, 2006
  2. [2]Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab 2006PubMed 17018654, 2006
  3. [3]FDA briefing document for the December 4, 2024 Pharmacy Compounding Advisory Committee meeting (CJC-1295 and CJC-1295 DAC evaluation: clinical adverse events, nonclinical toxicology, and FDA's proposal not to add them to the 503A bulks list)FDA, 2024
  4. [4]FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 and nominated but withdrawn substances, including CJC-1295)FDA, 2026
  5. [5]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (503A bulks list, Category 1, 2, and 3 lists, and withdrawn nominations)FDA, 2026
  6. [6]FDA prescribing information for Genotropin (somatropin) for injection, via DailyMed (Indications and Warnings and Precautions sections)FDA, 2026
  7. [7]Liu H et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007PubMed 17227934, 2007
  8. [8]WADA Prohibited List, section S2 (growth hormone releasing hormone and its analogues, including CJC-1295)WADA, 2026
  9. [9]Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014PubMed 25331030, 2014
  10. [10]Bowers CY et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab 1990PubMed 2108187, 1990

More from the blog